SpliceBio is a a genetic medicines company harnessing its proprietary Protein Splicing platform to develop the next generation of gene therapies. The Company’s platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by adeno-associated virus (AAV) vectors. The company’s lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research.